ANATOMIC STAGE/PROGNOSTIC GROUPS

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IA</td>
<td>T1*</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IB</td>
<td>T1a</td>
<td>N1mi</td>
<td>M0</td>
</tr>
<tr>
<td>IIA</td>
<td>T0</td>
<td>N1**</td>
<td>M0</td>
</tr>
<tr>
<td>IIB</td>
<td>T2a</td>
<td>T1*</td>
<td>N1**</td>
</tr>
<tr>
<td>IIIA</td>
<td>T0</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>IIIB</td>
<td>T2b</td>
<td>N3</td>
<td>T1a</td>
</tr>
<tr>
<td>IIIc</td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIIc</td>
<td>Any</td>
<td>T</td>
<td>N3</td>
</tr>
<tr>
<td>IV</td>
<td>Any</td>
<td>T</td>
<td>Any</td>
</tr>
</tbody>
</table>

**Primary Tumor (T)**
- **T1**: Tumor ≤ 20 mm in greatest dimension
  - **T1mi**: Tumor ≤ 1 mm in greatest dimension
  - **T1a**: Tumor > 1 mm but ≤ 5 mm in greatest dimension
  - **T1b**: Tumor > 5 mm but ≤ 10 mm in greatest dimension
  - **T1c**: Tumor > 10 mm but ≤ 20 mm in greatest dimension
- **T2**: Tumor > 20 mm but ≤ 50 mm in greatest dimension
- **T3**: Tumor > 50 mm in greatest dimension

**Notes**
- **T1** includes T1mi.
- **T2** and **T1** tumors with nodal micrometastases only are excluded from Stage IA and are classified Stage IB.
- **M0** includes M0(i+).
- **The designation pM0 is not valid; any M0 should be clinical.**
- **If a patient presents with M1 prior to neoadjuvant systemic therapy, the stage is considered Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.**
- **Stage designation may be changed if post-surgical imaging studies reveal the presence of distant metastases, provided that the studies are carried out within 4 months of diagnosis in the absence of disease progression and provided that the patient has not received neoadjuvant therapy.**
- **Post-neoadjuvant therapy is designated with “yp” or “yp” prefix. Of note, no stage group is assigned if there is a complete pathologic response (CR) to neoadjuvant therapy, for example, ypT0ypN0cM0.**

**Distant Metastases (M)**
- **M0**: No clinical or radiographic evidence of distant metastases
  - **cM0(i+)**: No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases
- **M1**: Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm

**Financial support for AJCC 7th Edition Staging Posters provided by the American Cancer Society**
Regional Lymph Nodes (N)

**CLINICAL**

NX Regional lymph nodes cannot be assessed (for example, previously removed)

N0 No regional lymph node metastases

N1 Metastases to movable ipsilateral level I, II, and III axillary lymph node(s)

N2 Metastases in ipsilateral level I, II, and III axillary lymph node(s) that are clinically fixed or matted; or in clinically detected* ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases

N2a Metastases in ipsilateral level I, II, and III axillary lymph node(s) fixed to one another (matted) or to other structures

N2b Metastases only in clinically detected* ipsilateral internal mammary nodes and in the absence of clinically evident level I, II, and III axillary lymph node metastases

N3 Metastases in ipsilateral infraclavicular lymph node(s) with or without level I, II, or III axillary lymph node involvement; or in clinically detected* ipsilateral internal mammary lymph node(s) with clinically evident level I, II, and III axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement

N3a Metastases in ipsilateral infraclavicular lymph node(s)

N3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)

N3c Metastases in ipsilateral supraclavicular lymph node(s)

**Notes**

* Clinically detected is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. Confirmation of clinically detected metastatic disease by fine needle aspiration without excision biopsy is designated with an (f) suffix, for example, cN1(f). Excisional biopsy of a lymph node or biopsy of a sentinel node, in the absence of assignment of a pT, is classified as a clinical N, for example, cN1. Information regarding the confirmation of the nodal status will be designated in site-specific biopsy of a sentinel node, in the absence of assignment of a pT, is classified as a clinical N, for example, cN1. Information regarding the confirmation of the nodal status will be designated in site-specific classification (pN) is used for excision or sentinel lymph node biopsy only in conjunction with a pathologic T assignment.

**PATHOLOGIC (PN)**

pNX Regional lymph nodes cannot be assessed (for example, previously removed, or not removed for pathologic study)

pN0 No regional lymph node metastasis identified histologically

Noted: Isolated tumor cell clusters (ITC) are defined as small clusters of cells not greater than 0.2 mm, or single tumor cells, or a cluster of fewer than 200 cells in a single histologic cross-section. ITC may be detected by routine histology or by immunohistochemical (IHC) methods. Nodes containing only ITCs are excluded from the total positive node count for purposes of N classification but should be included in the total number of nodes evaluated.

pN0(i−) No regional lymph node metastases histologically, negative IHC

pN0(i+) Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&E or IHC, including ITC)

pN0(mol−) No regional lymph node metastases histologically, negative molecular findings (RT-PCR)

pN0(mol+) Positive molecular findings (RT-PCR)*, but no regional lymph node metastases detected by histology or IHC

pN1 Micrometastases; or metastases in 1–3 axillary lymph nodes; and/or in internal mammary lymph nodes with metastases detected by sentinel lymph node biopsy but not clinically detected***

pN1mi Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm)

pN1a Metastases in 1–3 axillary lymph nodes, at least one metastasis greater than 2.0 mm

pN1b Metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected***

pN1c Metastases in 1–3 axillary lymph nodes and internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected

pN2 Metastases in 4–9 axillary lymph nodes; or in clinically detected**** internal mammary lymph nodes in the absence of axillary lymph node metastases

pN2a Metastases in 4–9 axillary lymph nodes (at least one tumor deposit greater than 2.0 mm)

pN2b Metastases in clinically detected**** internal mammary lymph nodes in the absence of axillary lymph node metastases

pN3 Metastases in 10 or more axillary lymph nodes; or in infracarciacicular (level III axillary) lymph nodes; or in clinically detected**** ipsilateral internal mammary lymph nodes in the presence of one or more positive level I, II, or III axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected***; or in ipsilateral infraclavicular lymph nodes

pN3a Metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infracarciacicular (level III axillary) lymph nodes

pN3b Metastases in clinically detected**** ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected***

pN3c Metastases in ipsilateral supraclavicular lymph nodes

**Notes**

* Classification is based on axillary lymph node dissection with or without sentinel lymph node biopsy. Classification based solely on sentinel lymph node biopsy without subsequent axillary lymph node dissection is designated (sn) for “sentinel node,” for example, pN0(sn).

**RT-PCR:** reverse transcriptase/polymerase chain reaction.

*** "Clinically detected" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination.

**** "Clinically detected" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination.